EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Feasibility of [18F]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study

Shahriar Islam, Marianna Inglese, Matthew Grech-Sollars, Preetha Aravind, Suraiya Dubash, Tara D Barwick, Kevin O'Neill, James Wang, Azeem Saleem, James O'Callaghan, Giulio Anchini, Matthew Williams und 2 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2023

DOI: 10.1007/s00259-023-06330-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2023. Verfasst von Shahriar Islam und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NIHR Imperial Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

MRI and PET are used in neuro-oncology for the detection and characterisation of lesions for malignancy to target surgical biopsy and to plan surgical resections or stereotactic radiosurgery. The critical role of short-chain fatty acids (SCFAs) in brain tumour biology has come to the forefront. The non-metabolised SCFA radiotracer, [ 18 F]fluoropivalate (FPIA), shows low background signal in most tissues except eliminating organs and has appropriate human dosimetry. Tumour uptake of the radiotracer is, however, unknown. We investigated the uptake characteristics of FPIA in this pilot PET/MRI study.

Methods

Ten adult glioma subjects were identified based on radiological features using standard-of-care MRI prior to any surgical intervention, with subsequent histopathological confirmation of glioma subtype and grade (lower-grade – LGG – and higher-grade – HGG – patients). FPIA was injected as an intravenous bolus injection (range 342–368 MBq), and dynamic PET and MRI data were acquired simultaneously over 66 min.

Results

All patients tolerated the PET/MRI protocol. Three patients were reclassified following resection and histology. Tumour maximum standardised uptake value (SUV max,60 ) increased in the order LGG (WHO grade 2) < HGG (WHO grade 3) < HGG (WHO grade 4). The net irreversible solute transfer, Ki, and influx rate constant, K1, were significantly higher in HGG ( p < 0.05). Of the MRI variables studied, DCE-MRI-derived extravascular-and-extracellular volume fraction (v e ) was high in tumours of WHO grade 4 compared with other grades ( p < 0.05). SLC25A20 protein expression was higher in HGG compared with LGG.

Conclusion

Tumoural FPIA PET uptake is higher in HGG compared to LGG. This study supports further investigation of FPIA PET/MRI for brain tumour imaging in a larger patient population. Clinical trial registration Clinicaltrials.gov, NCT04097535.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBrain NeoplasmsAdultHumansPilot ProjectsProspective StudiesFeasibility StudiesNeoplasm GradingPositron-Emission TomographyMagnetic Resonance ImagingMembrane Transport Proteins

Stichwörter der Autor:innen

FPIAGliomaPET/MRIShort-chain fatty acid[18F]fluoropivalate

Substanzen

SLC25A20 protein, humanMembrane Transport Proteins

Autor:innen und Institutionen

  • Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK.
  • Department of Brain Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK.
  • Invicro Limited, Burlington Danes Building, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK.
  • Hull York Medical School, University of Hull, Cottingham Road, Hull, HU6 7RX, UK.
  • Centre for Clinical Brain Sciences, University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.
  • Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK. eric.aboagye@imperial.ac.uk.

Förderung

  • Medical Research Council
  • NIHR Imperial Biomedical Research Centre

Zitieren

APA

Islam, S., Inglese, M., Grech-Sollars, M., Aravind, P., Dubash, S., Barwick, T. D., O'Neill, K., Wang, J., Saleem, A., O'Callaghan, J., Anchini, G., Williams, M., Waldman, A., & Aboagye, E. O. (2023). Feasibility of [18F]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06330-0

Vancouver

Islam S, Inglese M, Grech-Sollars M, Aravind P, Dubash S, Barwick TD, et al. Feasibility of [18F]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study. European Journal of Nuclear Medicine and Molecular Imaging. 2023. doi:10.1007/s00259-023-06330-0

BibTeX
@article{Islam2023,
  author = {Islam, Shahriar and Inglese, Marianna and Grech-Sollars, Matthew and Aravind, Preetha and Dubash, Suraiya and Barwick, Tara D and O'Neill, Kevin and Wang, James and Saleem, Azeem and O'Callaghan, James and Anchini, Giulio and Williams, Matthew and Waldman, Adam and Aboagye, Eric O},
  title = {Feasibility of [18F]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2023},
  doi = {10.1007/s00259-023-06330-0}
}
Kostenlos starten →